About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact
 
 
 

2012 | 2011 | 2010 | 2009 | 2008

EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity
December 28, 2011


EnteroMedics Receives First Approval for the Active Implantable Medical Device Components of the Maestro System From Australian Therapeutic Goods Administration (TGA)
December 13, 2011


Inviragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
December 7, 2011


Inviragen Initiates a Phase 2 Clinical Study of DENVax, a Recombinant, Tetravalent Dengue Vaccine
November 28, 2011


EnteroMedics Announces Updated Data From VBLOC DM2 ENABLE Study and Caloric Intake Study Results to Be Presented at the 29th Annual Obesity Society Meeting
October 3, 2011


EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
September 2, 2011


Inviragen and University of Texas Medical Branch Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine
August 15, 2011


San Diego's KFx Medical Corporation Files Patent Infringement Suit Against Arthrex
August 2, 2011


International Vaccine Institute and Inviragen Announce a Collaboration to Accelerate Development of a Dengue Vaccine
August 2, 2011


Minimally Invasive Devices, Inc. Awarded CE Mark for FloShield
July 20, 2011


XLUMENA RECEIVES CE MARK FOR NAVIX™, SECOND PRODUCT TO ENTER EUROPEAN MARKET
June 30, 2011


Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore
June 15, 2011


EnteroMedics Announces Maestro® RC System Updated Weight Loss Data to Be Presented at the American Society for Metabolic and Bariatric Surgery Annual Meeting
June 14, 2011


EnteroMedics Announces First Implant in ReCharge Pivotal Trial for Obesity
May 18, 2011


XLUMENA RECEIVES CE MARK FOR REVOLUTIONARY AXIOS™ STENT AND DELIVERY SYSTEM
May 5, 2011


Xlumena, Inc. Closes $7M Series B Venture Financing Round
April 28, 2011


EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward
March 28, 2011


Inviragen and Duke-NUS Form Collaborative Vaccine Research and Development Program
January 26, 2011

 
     
 

Minimally Invasive Devices, Inc. Awarded CE Mark for FloShield

Certification paves way for sale of innovative FloShield laparoscopic visualization system throughout the European Union

Columbus, OH - July 20, 2011

PRNewswire -- Minimally Invasive Devices, Inc., (MID) has been awarded CE Mark Certification for its FloShield laparoscopic visualization system. This certification is mandatory for sale of certain medical devices in the European Union.

The FloShield system provides for an uninterrupted clear view during laparoscopic procedures. FloShield uses airflow from the insufflator to defog and deflect debris from the lens of the laparoscope without removing the scope from the abdominal cavity for cleaning. Surgeons have to interrupt surgery as often as ten times per hour to remove the scope and manually clean it. FloShield dramatically reduces, and often eliminates, interruptions to clean the lens. FloShield is the only medical device that prevents optics from becoming obscured.

"The advent of HD ten years ago was the last breakthrough in laparoscopic vision," says Wayne Poll, M.D, FloShield inventor and CEO of MID. "FloShield represents the last hurdle in laparoscopic visualization."

The FloShield system, which received FDA 510(k) approval in 2008, is in early distribution within the U.S., and in use at approximately 40 hospitals throughout the country. The system was certified ISO 13485 compliant in December of 2010, clearing the path for CE Marking.

"We have been contacted by several European and Asian distributors who are interested in FloShield," says Poll.

FloShield is manufactured in Franklin, OH. Poll says the company has more than tripled employment over the last two years from four full time employees to 14.

About Minimally Invasive Devices, Inc.
Minimally Invasive Devices, Inc. (MID) was founded in 2007, by Wayne Poll, M.D., a laparoscopic surgeon. MID's first market offering is the FloShield system of laparoscopic visualization devices. The FloShield franchise will soon add Flo-X, the first biocompatible agent with 510(k) clearance for washing the lens of the laparoscope in situ. The company is also developing complimentary technology that manages the entire air space in laparoscopic surgery, which will improve the environment and experience for laparoscopic surgeons.

Funding for the company was led by the Ohio TechAngel Funds with additional funding from three other Ohio-based angel funds including Queen City, NorthCoast and ECOTAF. MID has received venture funding from Charter Life Sciences and Reservoir Partners. The company is headquartered at 1275 Kinnear Rd., Columbus, OH in the TechColumbus technology business incubator. For more information, visit www.midsurgical.com

SOURCE Minimally Invasive Devices, Inc.

 
     
     
   
 
 
© 2006 CHARTER LIFE SCIENCES